Carbapenem-resistant Acinetobacter baumannii: Diversity of resistant mechanisms and risk factors for infection

Epidemiology and Infection

Volumn 140, Issue 1, 2012, Pages 137-145

  Kim, Y J ^a   Kim, S I ^a   Kim, Y R ^a   Hong, K W ^a   Wie, S H ^a   Park, Y J ^b   Jeong, H ^a   Kang, M W ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acinetobacter baumannii; antibiotic resistance; infection; molecular epidemiology; risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; COLISTIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BETA LACTAMASE OXA 23 GENE; BETA LACTAMASE OXA 51 GENE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA RESTRICTION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SEQUENCE HOMOLOGY; SPECIES DIVERSITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CHI-SQUARE DISTRIBUTION; CLUSTER ANALYSIS; CROSS INFECTION; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; REPUBLIC OF KOREA; RISK FACTORS; STATISTICS, NONPARAMETRIC; THIENAMYCINS;

EID: 82455208766     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811000744     Document Type: Article

References (34)

1. Bogaerts P, et al. Outbreak of infection by carbapenemresistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. Journal of Clinical Microbiology 2006; 44: 4189-4192. (Pubitemid 44737268)
2. Bou G, et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of betalactamases. Journal of Clinical Microbiology 2000; 38: 3299-3305.
3. Perez F, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2007; 51: 3471-3484. (Pubitemid 47519332)
4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clinical Microbiology and Infection 2006; 12: 826-836. (Pubitemid 44151282)
5. Bratu S, et al. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrobial Agents and Chemotherapy 2008; 52: 2999-3005.
6. Gur D, et al. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. Journal of Medical Microbiology 2008; 57: 1529-1532.
7. Lee K, et al. VIM- and IMP-type metallo-beta-lactamase- producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerging Infectious Diseases 2003; 9: 868-871. (Pubitemid 36801591)
8. Garner JS, et al. CDC definitions for nosocomial infections, 1988. American Journal of Infectious Control 1988; 16: 128-140.
9. Turton JF, et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. Journal of Clinical Microbiology 2006; 44: 2974-2976. (Pubitemid 44228598)
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
11. Tygacil package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2005.
12. Seifert H, et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis- generated fingerprints of Acinetobacter baumannii. Journal of Clinical Microbiology 2005; 43: 4328-4335. (Pubitemid 41298209)
13. Woodford N, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. International Journal of Antimicrobial Agents 2006; 27: 351-353.
14. Turton JF, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiology Letters 2006; 258: 72-77.
15. Ellington MJ, et al. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. Journal of Antimicrobial Chemotherapy 2007; 59: 321-322. (Pubitemid 47072076)
16. Carlone GM, et al. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. Journal of Clinical Microbiology 1986; 24: 330-332. (Pubitemid 16046386)
17. Pannek S, et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-argininebeta- naphthylamide. Journal of Antimicrobial Chemotherapy 2006; 57: 970-974.
18. Shi WF, et al. Inhibitory effects of reserpine and carbonyl cyanide m-chloro-phenylhydrazone on fluoroquinolone resistance of Acinetobacter baumannii. Chinese Medical Journal (English edition) 2005; 118: 340-343.
19. Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple- antimicrobialresistant clinical isolates of Acinetobacter baumannii- Acinetobacter calcoaceticus complex. International Journal of Antimicrobial Agents 2009; 33: 27-32.
20. Munoz-Price LS, Weinstein RA. Acinetobacter infection. New England Journal of Medicine 2008; 358: 1271-1281.
21. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Current Opinion in Investigational Drugs 2002; 3: 218-224. (Pubitemid 34456076)
22. Mussi MA, et al. CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for L-ornithine uptake. FEBS Letters 2007; 581: 5573-5578. (Pubitemid 350179764)
23. Siroy A, et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2005; 49: 4876-4883. (Pubitemid 41778897)
24. Mugnier PD, et al. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerging Infectious Diseases 2010; 16: 35-40.
25. Villegas MV, et al. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrobial Agents and Chemotherapy 2007; 51: 2001-2004. (Pubitemid 46903086)
26. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrobial Agents and Chemotherapy 2005; 49: 1432-1440. (Pubitemid 40463373)
27. Wieczorek P, et al. Multidrug resistant Acinetobacter baumannii - the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochemistry Cytobiology 2008; 46: 257-267.
28. Magnet S, Courvalin P, Lambert T. Resistance-nodulation- cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrobial Agents and Chemotherapy 2001; 45: 3375-3380. (Pubitemid 33107849)
29. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2007; 51: 2065-2069. (Pubitemid 46903095)
30. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical Infectious Diseases 2008; 46: 1254-1263. (Pubitemid 351589912)
31. Baran G, et al. Risk factors for nosocomial imipenemresistant Acinetobacter baumannii infections. International Journal of Infectious Diseases 2008; 12: 16-21.
32. Lautenbach E, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infection Control and Hospital Epidemiology 2009; 30: 1186-1192.
33. Jang TN, et al. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. Journal of Hospital Infection 2009; 73: 143-150.
34. Lee SO, et al. Risk factors for acquisition of imipenemresistant Acinetobacter baumannii: a case-control study. Antimicrobial Agents and Chemotherapy 2004; 48: 224-228.